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Abstract The rate of obesity in Japan, defined as having
a body mass index (BMI) of 25 kg/m2 or greater, is
reportedly at 24 %, a lower level of severe obesity than in
the EU and US. However, the incidence of obesity-related
health problems is reportedly higher among Asians. Lap-
aroscopic sleeve gastrectomy (LSG) is the most frequently
performed bariatric surgery in Japan and accounted for
54 % of such surgeries in 2011; procedures such as
laparoscopic adjustable gastric banding and laparoscopic
Roux-en-Y gastric bypass (LRYGB), practiced frequently
worldwide, were uncommon. Possible reasons include
concern over delayed postoperative discovery of gastric
cancer in LRYGB, and rapid adoption of the comparatively
simple LSG procedure. In type 2 diabetes mellitus (T2DM)
patients, where continued pursuit of medical treatment is
difficult and a potential exists for future deterioration of
diabetes-complicated diseases, the criterion for surgical
indication in the EU and US is a BMI of 30–35 kg/m2, with
priority given to BMI [35 kg/m2. For Asian patients, the
recommendation is to lower this indication criterion by
2.5 kg/m2. Efficacy of metabolic surgery is anticipated
particularly among T2DM patients with obesity compli-
cation, a short history of insulin treatment, and intact
insulin secreting ability, and in these cases bariatric surgery
should be contemplated.
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Abbreviations
WHO World Health Organization
NIH National Institutes of Health
IDF International Diabetes Federation
JGES Japan Gastroenterological Endoscopy Society
JASSO Japan Society for the Study of Obesity
JELTO Japan Research Society for Endoscopic and
Laparoscopic Treatment of Obesity
JSSO Japanese Society for the Surgery of Obesity and
Metabolic Disorders
BMI Body mass index
%EWL Percentage of excess weight loss
LRYGB Laparoscopic Roux-en-Y gastric bypass
LAGB Laparoscopic adjustable gastric banding
LSG Laparoscopic sleeve gastrectomy
EIGB Endoscopic intragastric balloon
BPD Biliopancreatic diversion
DJB Duodenojejunal bypass
T2DM Type 2 diabetes mellitus
GLP-1 Glucagon-like peptide-1
Introduction
At the 33rd Annual Session of the United Nations
Standing Committee on Nutrition held in 2006, the World
Health Organization (WHO) reported that nearly 300
million adults worldwide were severely obese. While the
definition of obesity in the EU and US as having a body
mass index (BMI) of 30 kg/m2 or greater places more
than one-third of the adult population within the category
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of obesity, some 6–10 million individuals are said to be
severely obese, with a BMI of 40 kg/m2 or greater. Based
on current trends, the rate of obesity in the US is pro-
jected to reach approximately 40 % by 2025 [1]. In Japan,
the Japan Society for the Study of Obesity (JASSO)
defines obesity as a BMI of 25 kg/m2 or greater.
According to recent surveys, BMI values are 25 or greater
in 24 % of the population, 30 or greater in 3 %, 35 or
greater in 0.5 %, and 40 or greater in 0.2 %, reflecting a
lower level of severe obesity than in the EU or US.
However, a WHO Expert Committee reported that the
incidence of health problems stemming from obesity is
higher among Asians [2]. While the general treatment for
obesity in Japan centers on medical treatments such as
dietary, behavioral, and exercise therapy, surgical treat-
ments termed ‘‘metabolic surgery’’ have been practiced
more recently. Our review article discusses the current
status of bariatric surgery in Japan and its effectiveness in
the treatment of obesity and diabetes.
Worldwide trends in bariatric surgery and current
status in Japan
Based on questionnaire survey results from 33 countries,
Buchwald et al. [3, 4] reported that more than 340,000
bariatric surgeries were performed worldwide in 2008. The
proportion of laparoscopic procedures among bariatric
surgeries was 63 % in 2003 but had reached 92 % in 2008.
Types of bariatric surgery are shown in Fig. 1. The relative
shares of various procedures in 2008 included 43 % lapa-
roscopic Roux-en-Y gastric bypass (LRYGB), 42 % lapa-
roscopic adjustable gastric banding (LAGB), and 5 %
laparoscopic sleeve gastrectomy (LSG). LAGB allows
adjustment of the band tightener after surgery and removal
of the band in reoperation and is also a comparatively
simple procedure. For these reasons, LAGB has increased
rapidly in North America and is predicted to become the
most frequently performed weight loss surgery in the near
future.
Bariatric surgery was first performed in Japan by
Kawamura et al. in 1982 [5]. The bariatric restrictive
procedure became eligible for insurance reimbursement in
1988 but did not achieve widespread dissemination for
reasons of technique and indication. However, the
increasing number of obese patients, growing societal
needs in response to obesity, and progress in laparoscopic-
assisted surgical techniques have produced remarkable
developments in the treatment of obesity. Kitano et al. [6]
introduced the endoscopic intragastric balloon (EIGB) to
Japan in December 2004 and LAGB in August 2005 and
have reported good results. But as of 2012, only 10 facil-
ities are performing bariatric surgery, and currently there
are few bariatric surgeons. According to the results from
the 1st questionnaire survey of the Japan Research Society
for Endoscopic and Laparoscopic Treatment of Obesity
(JELTO), the number of bariatric surgeries performed
between 2000 and 2009 was 340, while 228 procedures
were performed in 2010 and 2011, showing a nascent
awareness of obesity pathology and a wider discussion of
indications for surgical treatment [7]. However, the most
widely performed bariatric surgery in Japan is LSG,
accounting for 54 % in 2011, while LAGB, LRYGB, and
other such procedures performed frequently worldwide are
uncommon. Possible reasons include a concern over the
delayed postoperative discovery of gastric cancer in
LRYGB and rapid adoption of the comparatively simple
LSG procedure; another issue bearing mention is consid-













Fig. 1 Types of bariatric surgery. AGB adjustable gastric banding, SG sleeve gastrectomy, RYGB Roux-en-Y gastric bypass
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Indications for bariatric surgery
The objective of treatment for obesity is to improve
obesity-related diseases, without requisite attainment of a
standard body weight. Medical treatments such as dietary,
exercise, behavioral, and drug therapy are the treatments of
first choice for obesity, but many cases of severe obesity
are resistant to medical treatment and also present diffi-
culties in achievement of adequate weight loss and main-
tenance of body weight after weight loss. The US National
Institutes of Health (NIH) reports that more than 90 % of
patients on a medically managed weight loss program
ultimately regain weight within 1 year. For these patients
with severe obesity resistant to medical treatment, or
patients in end-stage obesity syndromes that require urgent
intervention for obesity-related diseases, surgical treatment
must be considered. In 1991, the NIH stated that severe
obesity patients (patients with a BMI of 40 kg/m2 or
greater, or those with a BMI of 35 kg/m2 or greater and
obesity-related disease) presenting a low likelihood of
positive results from any treatment other than surgical
treatment were indicated for bariatric surgery.
In 2006, a joint committee of the JASSO, the Japan
Gastroenterological Endoscopy Society (JGES), and the
Japan Society for Endoscopic Surgery created guidelines
for indication of obesity treatment by endoscopy and
endoscopic surgery [7]. One point of agreement was that
treatments such as EIGB and LAGB were approved for use
in Japan. However, the use of devices not yet medically
approved in both treatments led to a policy of restricting
clinical use to then-current advanced treatment hospitals.
Indication of bariatric surgery was restricted to patients
with a BMI of 35 kg/m2 or greater and obesity-related
disease resistant to medical treatment [8]. Thereafter, the
Japanese Society for the Surgery of Obesity and Metabolic
Disorders (JSSO) prepared a ‘‘2010 Statement for Safe and
Exceptional Surgical Treatment for Severe Obesity in
Japan.’’ The statement defined surgical indication as BMI
C35 kg/m2 for a primary objective of weight loss and, with
reference to clinical research, as BMI C32 kg/m2 for a
primary objective of treatment for obesity-related disease
[9]. In 2011, the International Diabetes Federation (IDF)
called for a BMI of 30–35 kg/m2 to represent surgical
indication for type 2 diabetes mellitus (T2DM) unrespon-
sive to medical treatment, with priority to be given to BMI
[35 kg/m2 [9]. Surprisingly, the IDF also released a
statement recommending that this indication criterion be
lowered by 2.5 kg/m2 for Asian individuals [10].
In research carried out in France among more than 1,000
subjects undergoing LAGB in a 2-month period, outcomes
were interpreted as successful if the percentage of excess
weight loss (%EWL) at 2 years postoperatively was 50 %
or greater. Results were good among patients age 40 years
or younger, those with a BMI of \50 kg/m2 at initial
examination, and those demonstrating a return to physical
activity and changes in dietary habits. These were reported
as crucial factors for indication of LAGB and prediction of
weight loss effect. Good results were also reported in
facilities with abundant experience including two or more
weight loss surgeries in a 1-week period, and the adop-
tion of a team treatment system was recommended [11].
Pontiroli et al. [12] stated that periodic outpatient visits
were an important positive factor for prediction of LAGB
outcomes, and in contrast, self-centered personality was an
important negative factor. These factors are regarded as
crucial for achieving successful bariatric surgery.
Types of bariatric surgery and effects
EIGB represents an endoscopic treatment (in general terms,
a surgical treatment) for severe obesity. Surgical treatments
are classified as restrictive procedures, in which the
stomach is reduced in size to restrict food intake, malab-
sorptive procedures, in which nutrient absorption capacity
is reduced by application of a surgical procedure to the
small intestine, and procedures combining both of these
techniques. Examples of restrictive procedures include
LAGB and LSG, an example of a malabsorptive proce-
dures is biliopancreatic diversion (BPD), which shortens
the small intestine, through which food transits; and
examples of treatments combining both a restrictive pro-
cedure and a malabsorptive procedure include LRYGB and
LSG with duodenojejunal bypass (LSG/DJB). Though
there are as of yet few reports of weight loss results from
bariatric surgery in Japan, good weight loss outcomes
equivalent to those among Europeans and Americans have
been realized (Table 1) [7, 13, 14]. In contrast, rates of
bariatric surgical complication are 25.3 % in LRYGB,
5.1 % in LAGB, 15.3 % in LSG, and 15.5 % in LSG/DJB.
These rates are somewhat higher than those outside Japan
due to a lack of quantitative experience, indicating that
practiced technique and team treatment are crucial
(Table 2) [15].
EIGB
EIGB as reported in 1982 involved numerous material-
related complications, and long-term implantation was
problematic. The debut of the BIB (OrberaTM) system in
the US allowed 6-month implantation, leading to world-
wide use. The most recent materials prepared by the
manufacturer of the OrberaTM system (Allergan, Inc.) state
that EIGB is optimally indicated for patients with a
BMI of approximately 27–35 kg/m2 [16]. EIGB is also
J Gastroenterol (2014) 49:57–63 59
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well-indicated as a preoperative treatment intended to
mitigate perioperative risk in Class 2–3 obesity
(40 [ BMI C 30 kg/m2) accompanied by severe health
problems or among extremely obese patients (BMI
C50 kg/m2). EIGB is a treatment performed under gas-
troscopic observation in which physiological saline
including 400–700 ml of methylene blue is injected into a
gastric balloon inserted transorally as a technique to reduce
gastric capacity and the amount of food intake. Removal is
also possible and is accomplished by transoral endoscope,
using a specialized remover kit. In Japan, the BIB system
was introduced by Kitano et al. [6] in 2004, and Ohta et al.
[17] reported the first Japanese clinical results for 21 cases
in which the BIB system was used. No serious compli-
cations were found in this research, and weight loss (17
cases) at 5 months after balloon implantation was 12 kg,
while %EWL was 27 %. The improvement rate for
obesity-related disease was 80 % (8/10) in hypertension,
86 % in dyslipidemia (12/14), 100 % (9/9) in liver dys-
function, 100 % (10/10) in metabolic syndrome, and
100 % (5/5) in diabetes, reflecting good results. However,
they reported that two patients (9.5 %) required early
removal (within 1 week) of the balloon due to continuous
abdominal discomfort. They also reported that four patients
maintained a %EWL [20, and that the remaining four
patients returned to their pretreatment weight (%EWL at
12 months after balloon removal: 27 ± 12 vs 0.2 ± 2.1,
P \ 0.01). Genco et al. [18] investigated 2,515 cases of
intragastric balloon implantation in multicenter collabora-
tive research and reported that %EWL 6 months postop-
eratively was 34 %, while the rate of complications was
2.8 % (0.76 % gastric obstruction, 0.19 % gastric rupture,
0.36 % balloon rupture).
LAGB
LAGB is a restrictive procedure in which a silicone band is
wrapped around the upper portion of the stomach and
restricts food intake. An adjustable band was developed in
1986, and use in laparoscopic surgery began in 1993. Food
is digested and absorbed along the physiological route.
Today, a tool (Lap-Band; INAMED Co.) allowing
adjustment of band tightness has been developed, and
adjustment is accomplished through an access point
embedded subcutaneously. Typically, the device is
implanted by the pars flaccida technique (an approach from
the avascular portion of the lesser omentum), and several
gastric–gastric sutures are made to prevent band slippage.
Benefits include the ability to adjust band tightness post-
operatively, to remove the band by reoperation and return
to the preoperative state, and to perform postoperative
endoscopy in normal fashion. The difficulty of the surgical
technique in LAGB is lower than that in LRYGB, and
complications are also less frequent, leading to perfor-
mance in many countries. However, the weight loss effect
and the improvement rate in obesity-related diseases are
slightly lower than those in LRYGB, and depending on
postoperative symptoms, several band adjustments may
be necessary. Surgical indication must be considered
carefully.
According to a systematic review reported by Buchwald
et al. [19], mean postoperative %EWL by surgical tech-
nique was 47.5 % in LAGB and 61.6 % in LRYGB,
reflecting significance for LRYGB versus LAGB. Similar
results have also been reported in multicenter, randomized
clinical research. Nguyen et al. [20] compared 86 cases of
LAGB and 111 cases of LRYGB and reported that 4-year
postoperative %EWL was 45.4 % in LAGB and 68.4 % in
LRYGB. Himpens et al. [21] compared 40 cases of LAGB
Table 1 Outcomes of major bariatric procedures










LRYGB 147 76 77 74
LSG 102 66 68 –








LRYGB 1,615 61.5 69.7 71.2
LAGB 5,768 42.6 50.3 55.2
JELTO Japan Research Society for Endoscopic and Laparoscopic
Treatment of Obesity, LRYGB laparoscopic Roux-en-Y gastric bypass,
LSG laparoscopic sleeve gastrectomy, LAGB laparoscopic adjustable
gastric banding, %EWL percentage of excess weight loss









Total (%) 25.3 5.1 15.3 15.5
Intraoperative
(%)




1.1 1.7 1.9 3.6
Leakage 0 0 1.9 1.2
Anastomotic
stenosis
15.4 0 0 0
Reoperation
(%)
9.9 5.1 5.1 7.1
LRYGB laparoscopic Roux-en-Y gastric bypass, LAGB laparoscopic
adjustable gastric banding, LSG laparoscopic sleeve gastrectomy,
LSG/DJB laparoscopic sleeve gastrectomy with duodenojejunal
bypass
60 J Gastroenterol (2014) 49:57–63
123
and 40 cases of LSG and reported that the 3-year postop-
erative %EWL was 48 % in LAGB and 66 % in LSG.
As of yet there are few reports of long-term results for
LAGB in Japan. Ohta et al. [22] performed LAGB in 27
Japanese cases of severe obesity with a mean BMI of
41 kg/m2 and reported that the 5-year postoperative
%EWL was 56 %. Kasama et al. [23] performed LAGB in
13 cases of severe obesity with a mean BMI of 37.5 kg/m2
and reported that 18-month postoperative reduction of
excess BMI was 69.6 %.
LRYGB
LRYGB is a surgical technique combining a restrictive
procedure and a malabsorptive procedure, and accounted
for 66 % of bariatric surgeries (35 % laparoscopic sur-
geries, 31 % laparotomies) performed worldwide in 2002
and 2003 [3]. The surgical technique entails the separation
of the upper portion of the stomach with an automatic
suturing device to reduce the gastric capacity by 15–30 ml.
The jejunum is separated with an automatic suturing device
at a location approximately 50 cm from the Treitz liga-
ment, and the jejunum is lifted on the anal side and
mechanically anastomosed to the contracted stomach. The
length of the Roux-Y leg is approximately 75 cm in the
standard surgical technique and approximately 150 cm in
extremely obese patients (BMI C50 kg/m2). The absorp-
tive and digestive capacity of the alimentary system is thus
reduced, providing an effective reduction of capacity.
At a %EWL of 62 %, better results have been reported
than in EIGB and LAGB. Improvement in obesity-related
disease was 86 % in diabetes, 79 % in hypertension, 79 %
in hyperlipidemia, and 84 % in sleep apnea syndrome. The
rate of postoperative complications was 5 %, and the rate
of surgical deaths was 0.5 % [3]. LRYGB is the most
frequently performed bariatric surgery worldwide, per-
formed in approximately 80 % of cases in the US. Adams
et al. [24] investigated death rates comparatively during a
mean 7.1-year observational period among 7,925 age-, sex-
, and BMI-matched subjects in an RYGB cohort and 7,925
subjects in a control cohort (BMI C35 kg/m2). The death
rate in the RYGB cohort was 40 % lower than among
controls. Death rates in obesity-related disease were
reportedly reduced by 56 % for coronary artery disease,
92 % for diabetes, and 60 % for cancer. However, death
rates from causes unrelated to obesity such as accidents and
suicide were reportedly higher than in the control cohort,
making future trends in RYGB of interest. Considering that
the current incidence of gastric cancer in Japan is higher
than that in the EU and US, the difficulty that RYGB
presents to examination of the residual stomach calls for a
prudent stance on indication of RYGB in Japan.
LSG
LSG, used as an initial bariatric surgery for severely obese
patients, is a new technique for lowering rates of compli-
cation and surgical death. Though its efficacy has drawn
attention, it was not recommended by the 2004 American
Society for Bariatric Surgery Consensus Conference on
Bariatric Surgery. The surgical technique involves inser-
tion of a 40–60 Fr esophageal bougie into the stomach and
gastric excision with an automatic suturing device from the
greater curvature of the pyloric portion, approximately
5 cm proximally from the pyloric ring, toward the angle of
His. The intent is to reduce gastric capacity to 60–200 ml,
and if a sufficient capacity-reducing effect is not achieved,
a secondary RYGB or other such treatment is pursued.
For this new surgical technique, further study of long-
term results is needed, but 19,605 cases of LSG were
investigated at the Third International Summit for LSG
held in 2010. Overweight reduction rates at 1, 2, 3, 4, and
5 years postoperatively were 62.7, 64.7, 64.0, 57.3, and
60.0 %, respectively [13]. Reported complications were
1.3 % high leaks, 0.5 % lower leaks, and a 0.1 % rate of
death, and the surgical technique was evaluated as safe.
From studies in Asia, Moon Han et al. [25] reported a good
weight reduction of 72 % mean %EWL at 6 months
postoperatively and 83 % at 1 year in short-term results for
130 cases of LSG among obese patients with a mean BMI
of 37.2 kg/m2. Sasaki et al. [26] reported good results for
median %EWL, at 56 (42–70) % at 6 months postopera-
tively, and 68 (49–87) % at 1 year in short-term results for
seven LSG cases among severe obesity patients with a
median BMI of 47 kg/m2. Tagaya et al. [27] investigated
short-term results comparatively in 30 cases among obese
patients with a mean BMI of 49.1 kg/m2, comparing results
for BMI of \50 kg/m2 and BMI of C50 kg/m2. They
reported good results for patients with BMI of\50 kg/m2,
i.e., mean BMI of 27.8 versus 52.2 kg/m2, at 12 months
postoperatively and 29.7 versus 45.5 kg/m2 at 18 months
postoperatively. These reports show that LSG alone has the
potential to produce good results among Asian patients
with severe obesity represented by a BMI of \50 kg/m2,
and given that the procedure does not use specialized
devices awaiting medical approval, further adoption is
anticipated.
Improvement of obesity-related disease
The objective of bariatric surgery is not weight loss alone,
but also improvement of prognosis in obesity-related dis-
ease. Sjo¨stro¨m et al. [28] compared long-term results pro-
spectively among 2,010 cases undergoing weight loss
surgery and a medically treated control cohort of 2,037
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cases matched on 18 indices, including sex, age, and body
weight. In the control cohort, no long-term weight loss
effect was observed, while in the surgical cohort, change in
body weight plateaued at approximately 10 years postop-
eratively, after which the weight loss effect was main-
tained. This study reported that the effect on survival rates
from weight reduction and improvement of obesity-related
diseases was a 29 % reduced risk of death in the surgical
cohort versus controls.
Weight loss surgery has an improving effect on obesity-
related disease additional to that of body weight reduction
and has more recently been termed ‘‘metabolic surgery’’.
RYGB has a reportedly greater improvement effect on
diabetes than food intake restriction surgery. Though the
mechanism is not understood, two current theories exist. In
one, the ‘‘hindgut hypothesis’’, bypass of the upper small
intestine diverts food directly to the lower small intestine,
where glucagon-like peptide-1 (GLP-1) secretory cells
exist, thus promoting GLP-1 secretion. In another, the
‘‘foregut hypothesis’’, an as-yet unknown glucose tolerance
complicating factor which inhibits GLP-1 secretion is
secreted from the upper small intestine, and because bypass
surgery prevents food from passing through the upper small
intestine, this factor is no longer secreted [29].
Hutter et al. [30] reported that remission or improve-
ment rates on T2DM were 79 % in LRYGB and 55 % in
LSG, and outside Japan, there are many reports of better
results in LRYGB versus LSG. In Japan, however, LSG,
though a restrictive procedure, has been shown to have an
improving effect on diabetes rivaling that of LRYGB. In a
JELTO report, Ohta et al. [7] reported good results for
remission of T2DM (fasting glucose \110 mg/dl and
HbA1c \6 % without medication) from LSG, specifically,
91 % in LSG, 88 % in LRYGB, and 63 % in LAGB
(Table 3). Sasaki [31] also reported achievement of com-
plete remission (fasting glucose \100 mg/dl and HbA1c
\5.8 % without medication) among seven T2DM patients
after LSG. Though the mechanism of improved glucose
tolerance after LSG is unknown, increased secretion of
GLP-1 after surgery has been observed, as reported in
LRYGB [31]. Lee et al. [32] reported metabolic surgery
results in 200 cases of T2DM with a BMI of\35 kg/m2 in
Taiwan, South Korea, India, Japan, and Hong Kong.
Remission rates for T2DM were high in cases of gastric
bypass surgery with a \5-year treatment history, BMI of
30–35 kg/m2, and 3 ng/ml or higher C-peptide. Kasama
et al. [33] also reported rapid improvement in glucose
tolerance over a period of several months and achievement
of complete remission in 91 % of cases when LSG/DJB
was performed. These results were realized primarily
among patients with severe T2DM receiving insulin and
manifesting low C-peptide levels, reduced initial insulin
secreting capacity in oral glucose load testing, kidney
disease, retinopathy, neuropathy, and other microangial
complications. This indicates that even simple LSG and
similar surgical procedures can provide remission of
T2DM in attempts to reduce body weight by restriction of
caloric intake among Japanese T2DM patients whose
essential pathology is regarded as insulin resistance in
conjunction with excess fat storage. At the same time,
bypass-based surgical procedures acting directly on insulin
secretion, combined with weight loss, are deemed to have
an ample antidiabetic effect among T2DM patients whose
essential pathology is regarded as impaired insulin
secretion.
Conclusion
The principles of obesity treatment are based on the med-
ical treatments of dietary and exercise therapy, which,
combined with behavioral therapy allowing long-term
maintenance, improve lifestyle habits. For patients with a
BMI of 35 kg/m2 or greater and obesity-related disease
resistant to medical treatment, bariatric surgery must be
considered, and its outcomes among Japanese individuals
are good, as in cases outside Japan. LRYGB and LSG also
offer increased GLP-1 secretion postoperatively, suggest-
ing a large potential for treatment of T2DM patients;
however, the associated mechanisms are unknown, and
further clinical research is needed. Bariatric surgery, which
offers the effects of metabolic surgery, should be consid-
ered for T2DM patients with difficulty in continuing
medical treatment and a potential for future deterioration
and diabetic complications. Bariatric surgery is particularly
well-indicated for T2DM patients with obesity complica-
tions, a short insulin treatment history, and intact insulin
secreting ability. From the medical economics perspective
of obesity and metabolic syndrome as well, minimally
Table 3 Remission and improvement rates of T2DM
Source Procedure No. of patients Remission (%)
JELTO [7] LRYGB 64 88
LSG 35 91
LAGB 19 63
Buchwald et al. [19] LRYGB 989 83.8
LAGB 205 47.8
Hutter et al. [30] LRYGB 4,452 79a
LSG 249 55a
LAGB 2,558 44a
T2DM type 2 diabetes mellitus, JELTO Japan Research Society for
Endoscopic and Laparoscopic Treatment of Obesity, LRYGB laparo-
scopic Roux-en-Y gastric bypass, LSG laparoscopic sleeve gastrec-
tomy, LAGB laparoscopic adjustable gastric banding
a Remission and improvement rates
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invasive bariatric surgery has substantial promise, and
insurance coverage in the near term is awaited.
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